The CHD1 Monoclonal Antibody (CAB23240) is a high-quality antibody developed for reliable detection and analysis of target proteins. The CHD family of proteins is characterized by the presence of chromo (chromatin organization modifier) domains and SNF2-related helicase/ATPase domains. CHD genes alter gene expression possibly by modification of chromatin structure thus altering access of the transcriptional apparatus to its chromosomal DNA template.
This antibody is validated for use in WB, ELISA applications and has demonstrated reactivity against Human samples.
Product Name:
CHD1 Monoclonal Antibody
SKU:
CAB23240
Size:
100μL, 20μL
Reactivity:
Human
Clone Number:
ARC59018
Conjugate:
Unconjugated
Immunogen:
Recombinant protein (or fragment).This information is considered to be commercially sensitive.
Tested Applications:
WBELISA
Recommended Dilution:
WB
1:1000 - 1:2000
ELISA
Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Synonyms:
CHD-1, PILBOS, CHD1
Positive Sample:
K-562
Cellular Localization:
Cytoplasm, Nucleus.
Calculated MW:
197 kDa
Observed MW:
250 kDa
The CHD family of proteins is characterized by the presence of chromo (chromatin organization modifier) domains and SNF2-related helicase/ATPase domains. CHD genes alter gene expression possibly by modification of chromatin structure thus altering access of the transcriptional apparatus to its chromosomal DNA template.
Purification Method
Affinity purification
Gene ID
1105
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol and 0.05% BSA, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of lysates from K-562 cells using CHD1 Rabbit mAb (CAB23240) at 1:1000 dilution incubated overnight at 4℃. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25 μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 45 s.
